Loading... Please wait...


Our Newsletter

PF-04217903 | cMet inhibitor

  • PF-04217903.jpg
  • PF-04217903, 400x400px, png
Catalog #:

Product Description

PF-04217903 is a triazolopyrazine-based, ATP-competitive inhibitor of c-Met with Ki and cellular IC50 potency of 4 nM and 5 nM, respectively. [1] In a broad panell of over 200 kinases, PF-04217903 showed >1000-fold selectivity for c-Met. For c-Met mutations, PF-04217903 exhibited activities of 6.4 nM, 6.7 nM, and 3.1 nM for endogenous c-Met-R988C, endogenous C-Met-T1010I, and entineered c-Met-H1094R, respectively. [3]

Additionally, PF-04217903 inhibited proliferation, cell survival, migration/invasion in MET-amplified cell lines in vitro and was efficacious in tumor models with either MET gene amplification or hepatocyte growth factor (HGF)/c-Met autocrine loop in vivo. [2, 4] Efficacy was dose-dependent and correlated with inhibition of c-Met phosphorylation and downstream signaling.

Due to its exquisite selectivity profile, PF-04217903 can be considered as a powerful tool in probing c-Met catalytic activity in preclinical models for cancer progression.

Technical information:

Chemical Formula:   C20H20N8O4S
CAS #:   956906-93-7
Molecular Weight:   468.49
Purity:   >98%
Appearance:   White
Chemical Name:   2-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-1H-pyrazol-1-yl)ethanol mesylate
Solubility:   Up to 15 mM in DMSO
Synonyms:   PF-04217903, PF 04217903, PF04217903

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Cui et al., Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J. Med. Chem. 2012, 55, 8091-8109. Pubmed ID: 22924734
2. Zou et al., Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol. Cancer Ther. 2012, 11, 1036-1047. Pubmed ID: 22389468
3. Timofeevski et al., Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry, 2009, 48, 5339-5349. Pubmed ID: 19459657
4. Shojaei et al., HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010, 70, 10090-10100. Pubmed ID: 22389468

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the PF-04217903 | cMet inhibitor to your wish list.

You Recently Viewed...